Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $15,283.34 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,343 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total value of $15,283.34. Following the transaction, the senior vice president now directly owns 122,330 shares in the company, valued at approximately $1,392,115.40. This represents a 1.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Dyne Therapeutics Trading Up 1.4 %

Shares of DYN stock opened at $12.05 on Friday. The stock has a 50 day moving average of $14.58 and a two-hundred day moving average of $25.27. Dyne Therapeutics, Inc. has a 12 month low of $11.18 and a 12 month high of $47.45. The company has a market capitalization of $1.36 billion, a P/E ratio of -3.38 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $50,000. Finally, KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the period. Institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of analyst reports. Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday, February 28th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Robert W. Baird initiated coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. BMO Capital Markets initiated coverage on Dyne Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Scotiabank initiated coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.85.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.